arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PROTHENA CORP PUBLIC LTD CO

PRTA
$8.68 ▼ -0.30 (-3.39%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
60 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PROTHENA CORP PUBLIC LTD CO faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $452.6M
Dividend Yield
Revenue Growth -77.1%
Op. Margin None
ROIC -7.4%
FCF / Share $-0.48
Trailing P/E
Price / Book 1.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

60-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.01M
↓ -77.1%
Net Income Profit after all expenses
$32.72M
— 0.0%
Operating Margin Operating profit as % of sales
58.8%
↑ +33.0%
FCF / Share Free cash flow per share
$-0.48
↓ -189.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality
47

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 60 quarters